Travere Therapeutics, Inc. (TVTX) Q1 FY26 Earnings Call

FSGS approval adds a larger opportunity to accelerating Filspari demand, with early payer access and uptake indicators favorable [3][5][6].

Q1 FY26 results, source: company transcript and SEC filings
QuarterQ1 FY26
Length49 minutes
EPS$-0.39
EPS consensus$-0.30
Revenue$127.2M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26

All TVTX earnings ยท Back to TVTX overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.